Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review
- Autores
- Pinazo, Maria-Jesús; Thomas, M Carmen; Bua, Jacqueline; Perrone, Alina E.; Schijman, Alejandro Gabriel; Viotti, Rodolfo; Ramsey, Janine-M; Ribeiro, Isabela; Sosa-Estani, Sergio; López, Manuel-Carlos; Gascon, Joaquim
- Año de publicación
- 2014
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Pinazo, Maria-Jesús. Centro de Investigación en Salud Internacional de Barcelona; España.
Fil: Thomas, M Carmen. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España.
Fil: Bua, Jacqueline. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.
Fil: Perrone, Alina E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.
Fil: Schijman, Alejandro Gabriel. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular. Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.
Fil: Viotti, Rodolfo. Hospital Eva Perón. Departamento de Cardiología; Argentina.
Fil: Ramsey, Janine-M. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; México.
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases Initiative; Suiza.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.
Fil: López, Manuel-Carlos. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España.
Fil: Gascon, Joaquim. Centro de Investigación en Salud Internacional de Barcelona; España.
The most neglected aspects of Chagas disease (CD) have been patient care and treatment. Despite recent progress in the development of potentially improved drugs, there is no consensus among different research groups on the lack of therapeutic response markers to evaluate efficacy of newly proposed drugs early after treatment. A systematic review of current evidence regarding molecules which are potential biomarkers for therapeutic response has been conducted using quality assessment and target responses as primary criteria. The review provides a panorama of the cumulative evidence and specific needs for development of a battery of complementary biomarkers which together fulfill ideal or acceptable criteria to evaluate early responses to treatment for chronic CD. There are several marker candidates which together may fulfill acceptable criteria to indicate the efficacy of a trypanocidal treatment. Data from ongoing studies are considered essential to improve assessment of existing markers and to identify those for early follow-up of treated patients. - Materia
-
Enfermedad de Chagas
Progresión de la Enfermedad
Tripanocidas
Biomarcadores - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- none
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:Publications/123456789/1458
Ver los metadatos del registro completo
| id |
SGCANLIS_e5f344028781d6020f11ba3aa518ef2c |
|---|---|
| oai_identifier_str |
oai:sgc.anlis.gob.ar:Publications/123456789/1458 |
| network_acronym_str |
SGCANLIS |
| repository_id_str |
a |
| network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| spelling |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic reviewPinazo, Maria-JesúsThomas, M CarmenBua, JacquelinePerrone, Alina E.Schijman, Alejandro GabrielViotti, RodolfoRamsey, Janine-MRibeiro, IsabelaSosa-Estani, SergioLópez, Manuel-CarlosGascon, JoaquimEnfermedad de ChagasProgresión de la EnfermedadTripanocidasBiomarcadoresFil: Pinazo, Maria-Jesús. Centro de Investigación en Salud Internacional de Barcelona; España.Fil: Thomas, M Carmen. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España.Fil: Bua, Jacqueline. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.Fil: Perrone, Alina E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.Fil: Schijman, Alejandro Gabriel. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular. Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.Fil: Viotti, Rodolfo. Hospital Eva Perón. Departamento de Cardiología; Argentina.Fil: Ramsey, Janine-M. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; México.Fil: Ribeiro, Isabela. Drugs for Neglected Diseases Initiative; Suiza.Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina.Fil: López, Manuel-Carlos. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España.Fil: Gascon, Joaquim. Centro de Investigación en Salud Internacional de Barcelona; España.The most neglected aspects of Chagas disease (CD) have been patient care and treatment. Despite recent progress in the development of potentially improved drugs, there is no consensus among different research groups on the lack of therapeutic response markers to evaluate efficacy of newly proposed drugs early after treatment. A systematic review of current evidence regarding molecules which are potential biomarkers for therapeutic response has been conducted using quality assessment and target responses as primary criteria. The review provides a panorama of the cumulative evidence and specific needs for development of a battery of complementary biomarkers which together fulfill ideal or acceptable criteria to evaluate early responses to treatment for chronic CD. There are several marker candidates which together may fulfill acceptable criteria to indicate the efficacy of a trypanocidal treatment. Data from ongoing studies are considered essential to improve assessment of existing markers and to identify those for early follow-up of treated patients.2014-04info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://sgc.anlis.gob.ar/handle/123456789/145810.1586/14787210.2014.899150Expert review of anti-infective therapynoneinfo:eu-repo/semantics/openAccessengreponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLIS2025-09-29T14:30:20Zoai:sgc.anlis.gob.ar:Publications/123456789/1458Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:30:20.761Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
| dc.title.none.fl_str_mv |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| title |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| spellingShingle |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review Pinazo, Maria-Jesús Enfermedad de Chagas Progresión de la Enfermedad Tripanocidas Biomarcadores |
| title_short |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| title_full |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| title_fullStr |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| title_full_unstemmed |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| title_sort |
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review |
| dc.creator.none.fl_str_mv |
Pinazo, Maria-Jesús Thomas, M Carmen Bua, Jacqueline Perrone, Alina E. Schijman, Alejandro Gabriel Viotti, Rodolfo Ramsey, Janine-M Ribeiro, Isabela Sosa-Estani, Sergio López, Manuel-Carlos Gascon, Joaquim |
| author |
Pinazo, Maria-Jesús |
| author_facet |
Pinazo, Maria-Jesús Thomas, M Carmen Bua, Jacqueline Perrone, Alina E. Schijman, Alejandro Gabriel Viotti, Rodolfo Ramsey, Janine-M Ribeiro, Isabela Sosa-Estani, Sergio López, Manuel-Carlos Gascon, Joaquim |
| author_role |
author |
| author2 |
Thomas, M Carmen Bua, Jacqueline Perrone, Alina E. Schijman, Alejandro Gabriel Viotti, Rodolfo Ramsey, Janine-M Ribeiro, Isabela Sosa-Estani, Sergio López, Manuel-Carlos Gascon, Joaquim |
| author2_role |
author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Enfermedad de Chagas Progresión de la Enfermedad Tripanocidas Biomarcadores |
| topic |
Enfermedad de Chagas Progresión de la Enfermedad Tripanocidas Biomarcadores |
| dc.description.none.fl_txt_mv |
Fil: Pinazo, Maria-Jesús. Centro de Investigación en Salud Internacional de Barcelona; España. Fil: Thomas, M Carmen. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España. Fil: Bua, Jacqueline. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina. Fil: Perrone, Alina E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina. Fil: Schijman, Alejandro Gabriel. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular. Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina. Fil: Viotti, Rodolfo. Hospital Eva Perón. Departamento de Cardiología; Argentina. Fil: Ramsey, Janine-M. Instituto Nacional de Salud Pública. Centro Regional de Investigación en Salud Pública; México. Fil: Ribeiro, Isabela. Drugs for Neglected Diseases Initiative; Suiza. Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitologia; Argentina. Fil: López, Manuel-Carlos. Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra; España. Fil: Gascon, Joaquim. Centro de Investigación en Salud Internacional de Barcelona; España. The most neglected aspects of Chagas disease (CD) have been patient care and treatment. Despite recent progress in the development of potentially improved drugs, there is no consensus among different research groups on the lack of therapeutic response markers to evaluate efficacy of newly proposed drugs early after treatment. A systematic review of current evidence regarding molecules which are potential biomarkers for therapeutic response has been conducted using quality assessment and target responses as primary criteria. The review provides a panorama of the cumulative evidence and specific needs for development of a battery of complementary biomarkers which together fulfill ideal or acceptable criteria to evaluate early responses to treatment for chronic CD. There are several marker candidates which together may fulfill acceptable criteria to indicate the efficacy of a trypanocidal treatment. Data from ongoing studies are considered essential to improve assessment of existing markers and to identify those for early follow-up of treated patients. |
| description |
Fil: Pinazo, Maria-Jesús. Centro de Investigación en Salud Internacional de Barcelona; España. |
| publishDate |
2014 |
| dc.date.none.fl_str_mv |
2014-04 |
| dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://sgc.anlis.gob.ar/handle/123456789/1458 10.1586/14787210.2014.899150 |
| url |
http://sgc.anlis.gob.ar/handle/123456789/1458 |
| identifier_str_mv |
10.1586/14787210.2014.899150 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Expert review of anti-infective therapy |
| dc.rights.none.fl_str_mv |
none info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
none |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
| reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
| instacron_str |
ANLIS |
| institution |
ANLIS |
| repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
| repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
| _version_ |
1844621856142786560 |
| score |
12.559606 |